Eric Hsu
Corporate Officer/Principal at INMED PHARMACEUTICALS INC.
Net worth: 19 $ as of 2024-03-30
Eric Hsu active positions
| Companies | Position | Start | End |
|---|---|---|---|
| INMED PHARMACEUTICALS INC. | Corporate Officer/Principal | 2018-03-12 | - |
Career history of Eric Hsu
Former positions of Eric Hsu
| Companies | Position | Start | End |
|---|---|---|---|
enGene, Inc.
 enGene, Inc. BiotechnologyHealth Technology enGene, Inc. develops therapeutic solutions for the treatment of metabolic diseases. It operates as a biotechnology company which develops a mucosal immunotherapy platform for treating several prevalent, chronic diseases including inflammatory bowel disease and diabetes. The firm also develops proprietary, non-integrating biopolymer based nucleotide DNA and siRNA delivery technology that facilitates localized delivery of immune-modulating proteins to the intestinal mucosa for treating various immune disorders. The company was founded in 1999 by Anthony T. Cheung, John C. Brown, Timothy J. Kieffer, and Francis John Gargiulo and is headquartered in Vancouver, Canada. | Chief Operating Officer | 2001-12-31 | 2017-12-31 |
| Chief Tech/Sci/R&D Officer | 2001-12-31 | 2017-12-31 |
Training of Eric Hsu
| McGill University | Undergraduate Degree |
| University of Toronto | Doctorate Degree |
Statistics
International
| Canada | 5 |
Operational
| Chief Operating Officer | 1 |
| Chief Tech/Sci/R&D Officer | 1 |
| Undergraduate Degree | 1 |
Sectoral
| Health Technology | 3 |
| Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| INMED PHARMACEUTICALS INC. | Health Technology |
| Private companies | 1 |
|---|---|
enGene, Inc.
enGene, Inc. BiotechnologyHealth Technology enGene, Inc. develops therapeutic solutions for the treatment of metabolic diseases. It operates as a biotechnology company which develops a mucosal immunotherapy platform for treating several prevalent, chronic diseases including inflammatory bowel disease and diabetes. The firm also develops proprietary, non-integrating biopolymer based nucleotide DNA and siRNA delivery technology that facilitates localized delivery of immune-modulating proteins to the intestinal mucosa for treating various immune disorders. The company was founded in 1999 by Anthony T. Cheung, John C. Brown, Timothy J. Kieffer, and Francis John Gargiulo and is headquartered in Vancouver, Canada. | Health Technology |
- Stock Market
- Insiders
- Eric Hsu
- Experience
